• 1
    Mendez E Lipton RB Dyer A Ramsey-Goldman R Roftcher P Bowyer Set al. Incidence of JDM 1995–1998 from the NIAMS Registry. Arthritis Rheum (Arthritis Care Res). In press.
  • 2
    Pachman LM, Mendez E, Lou H, Chung A, Davis V, Ramsey-Goldman R, et al. At diagnosis, African American children with juvenile dermatomyositis (JDM) may have a different presentation than Caucasian or Hispanic children: physician reported data from NIAMS JDM research registry. [abstract] Arthritis Rheum 1999; 42: Suppl 9 S184.
  • 3
    Pachman LM, Hayford JR, Chung A, Daugherty, Pallansch MA, Fink CW, et al. Juvenile dermatomyositis at diagnosis: clinical characteristics of 79 children. J Rheumatol 1998; 25: 1198204.
  • 4
    Rider LG. Assessment of disease activity and its sequelae in children and adults with myositis. Curr Opin Rheumatol 1996; 8: 495506.
  • 5
    Pachman LM. Imperfect indication of disease activity in juvenile dermatomyositis. J Rheumatol 1995; 22: 1937.
  • 6
    Rider LG, Feldman BM, Perez MD, Rennebohm RM, Lindsley CB, Zemel LS, et al. Development of validated disease activity and damage indices for juvenile idiopathic inflammatory myopathies: I Physician, parent and patients global assessments. Arthritis Rheum 1997; 40: 197683.
  • 7
    Lovell DJ, Lindsley CB, Rennebohm RM, Ballinger S, Bowyer SL, Feldman BM, et al. Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies: II The childhood myositis assessment scale (CMAS): a quantitative tool for the evaluation of muscle involvement. Arthritis Rheum 1998; 42: 22139.
  • 8
    Feldman BM, Ayling-Campos A, Luy L, Stevens D, Silverman ED, Laxer RM. Measuring disability in juvenile dermatomyositis: validity of the childhood health assessment questionnaire. J Rheumatol 1995; 22: 32631.
  • 9
    Huber AM, Hicks JE, Lachenbruch PA, Perez MD, Zemel LS, Rennebohm RM, et al. Validation of the childhood health assessment questionnaire in the juvenile idiopathic myopathies. Arthritis Rheum 2000; 43: 5419.
  • 10
    Pachman LM, Mendez E, Lechman T, Sundberg J, Shamiyeh E, Dyer A. The rash of juvenile dermatomyositis (JDM) is associated with derangement of capillaries. Arthritis Rheum 2000; 43 Suppl 9: S380.
  • 11
    Rider LG, Miller FW. Laboratory evaluation of the inflammatory myopathies. Clin Diag Lab Immunol 1995; 2: 19.
  • 12
    Eisenstein DM, O'Gorman MR, Pachman LM. Correlations between change in disease activity and changes in peripheral blood lymphocyte subsets in patients with juvenile dermatomyositis. J Rheumatol 1997; 24: 18302.
  • 13
    O'Gorman MRG, Corrochano V, Roleck J, Donovan M, Pachman LM. Flow cytometric analysis of the lymphocyte subsets in peripheral blood of children with untreated active juvenile dermatomyositis. Clin Diag Lab Immunol 1995; 2: 2058.
  • 14
    Pachman LM. Polymyositis and dermatomyositis in children. In: MaddisonPJ, IsenbergDA, WooP, GlassDN, editors. Oxford textbook of rheumatology, 2nd ed. Oxford, UK: Oxford University Press; 1998. p. 1287300.
  • 15
    Pachman LM. Juvenile dermatomyositis: new clues to diagnosis and pathogenesis. Clin Exp Rheumatol 1994; 12: 6973.
  • 16
    Pachman LM. Pathophysiology and disease expression. Pediatr Clin North Am 1995; 42: 107198.
  • 17
    Pachman LM, Maduzia L, Chung A, Donovan M, Ramsey-Goldman M. Juvenile dermatomyositis (JDMS): disease activity scores are correlated with levels of neopterin in serum. [abstract] Arthritis Rheum 1995; 38 Suppl 9: R13.
  • 18
    Pachman LM, Sundberg MJ, Maduzia L, Daugherty C, Litt D. Sequential studies of nailfold capillary vessels (NFC) in 10 children with juvenile dermatomyositis (JDMS): correlation with disease activity score (DAS) but not von Willebrand factor antigen (vWF:Ag). [abstract] Arthritis Rheum 1995; 38 Suppl 9: S361.
  • 19
    Guzman J, Petty RE, Malleson PN. Monitoring disease activity in juvenile dermatomyositis: the role of von Willebrand factor and muscle enzymes. J Rheumatol 1994; 21: 73943.
  • 20
    Bohan A, Peter JB. Polymyositis and dermatomyositis (parts 1 and 2). N Engl J Med 1975; 292: 3447, 403–7
  • 21
    Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23: 13745.
  • 22
    Singh G, Athreya BH, Fries JF, Goldsmith DP. Measurement of health status in children with juvenile rheumatoid arthritis. Arthritis Rheum 1994; 37: 17619.
  • 23
    Kendall F, McCreary EK, Provance PG. Muscles: testing and function. Baltimore: Williams & Willkins; 1993.
  • 24
    Resnick JS, Mammel M, Mundale MO, Kottke FJ. Muscle strength as an index of response to therapy in childhood dermatomyositis. Arch Phys Med Rehabil 1981; 62: 129.
  • 25
    Rasch G. Probabilistic models for some intelligence and attainment tests. Copenhagen: Danish Institute for Educational Research; 1960. (Expanded edition, Chicago: The University of Chicago Press; 1980).
  • 26
    Bond T, Fox C. Applying the Rasch model: fundamental measurement in the human sciences. Mahwah, NJ: Lawrence Erlbaum Associates; 2001.
  • 27
    Tsuiji T, Liu M, Sonoda S, Domen K, Chino N. The stroke impairment assessment set: its internal consistency and predictive validity. Arch Phys Med Rehabil 2000; 81: 8638.
  • 28
    Silverstein BJ, Fisher WP Jr, Kilgore KM, Harvey RF, Harley JP. Applying psychometric criteria to functional assessment in medical rehabilitation: I Defining interval measures. Arch Phys Med Rehabil 1992; 73: 50718.
  • 29
    Grimby G, Andren E, Holmgren E, Wright B, Linacre JM, Sundh V. Structure of a combination of functional independence and instrumental activity items in community living persons: a study of individuals with cerebral palsy and spina bifida. Arch Phys Med Rehabil 1996; 77: 110914.
  • 30
    Granger C, Linn R. Biologic patterns of disability. J Outcome Measure 2000; 4: 595615.
  • 31
    Tesio L, Granger CV, Fiedler RC. A unidimensional pain/disability measure for low-back pain syndromes. Pain 1997; 69: 26978.
  • 32
    Wolfe F, Kong S. Rasch analysis of the Western Ontario MacMaster Questionnaire (WOMAC) in 2205 patients with osteoarthritis, rheumatoid arthritis, and fibromyalgia. Ann Rheum Dis 1999; 58: 5638.
  • 33
    Wiren L, Whalley D, McKenna S, Wilhelmsen L. Application of a disease-specific, quality of life measure (QOL-ACHDA) in growth hormone-deficient adults and a random population sample in Sweden: validation of the measure by Rasch analysis. Clin Endocrin 2000; 52: 14352.
  • 34
    Doble S, Fisher AG. The dimensionality and validity of the Older Americans Resources and Services (OARS) Activities of Daily Living (ADL) Scale. J Outcome Measure 1998; 2: 424.
  • 35
    Wright BD, Masters GN. Rating scale analysis: Rasch measurement. Chicago: MESA Press; 1982.
  • 36
    Wright BD, Linacre JM. Winsteps: Rasch analysis computer program. Chicago: MESA Press; 2000.
  • 37
    Linacre JM. Many-facet Rasch measurement. Chicago: MESA Press; 1989.
  • 38
    Linacre JM, Wright BD. Facets: Rasch analysis computer program. Chicago: MESA Press; 2000.
  • 39
    Banker BQ. Dermatomyositis of childhood. J Neuropathol Exp Neurolol 1975; 34: 4675.
  • 40
    The Pediatric Rheumatology International Trials Organization. International Consensus Conference to Define Core Sets of Outcome Measures for Juvenile Systemic Lupus Erythematosus and Juvenile Dermatomyositis. Preliminary data. Pavia Italy, April